Developer docs
API playgroundTry for free, no card

Search company profiles

Dexcel Pharma

Full company profile

uuid02meb1h

Namestring
Dexcel Pharma
Legal namestring
Dexcel Pharma
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Dexcel Pharma is a privately owned pharmaceutical company headquartered in Or Akiva, Israel, with 1,001–5,000 employees. It develops, manufactures, and commercializes a diversified portfolio of branded prescription drugs, over-the-counter products (including national brands and private-label lines), and generic medicines—including established, niche, and first-to-market generics in various dosage forms. The company states R&D capabilities across multiple drug modalities: small molecules, biologics, oligonucleotides, and genetic medicine.

Dexcel commercializes its products globally through wholly-owned regional subsidiaries in five key markets—the United States (Dexcel USA), Israel (Dexcel Israel), the United Kingdom (Dexcel UK), Germany (Dexcel Germany), and Austria (Dexcel Austria)—supplemented by a network of third-party distributors and partners for broader geographic reach. Its customer base spans three primary segments: healthcare providers (physicians, hospitals, healthcare systems) for branded Rx, retail pharmacies and pharmaceutical distributors for OTC and generics, and end consumers purchasing OTC products through retail channels.

The revenue model is product-sale driven across all three product categories, with pricing not publicly disclosed. The company describes itself as investing in R&D and commercialization of novel drugs and technologies, and operates as an independent private entity with no disclosed parent company, institutional investors, M&A history, management roster, or financial metrics in the available source material.

Short descriptiontext

Dexcel Pharma is a privately held Israeli pharmaceutical company that develops, manufactures, and commercializes branded prescription drugs, generic medicines, and OTC products across multiple dosage forms. It serves healthcare providers, pharmacies, distributors, and consumers through subsidiaries in the US, Israel, UK, Germany, and Austria.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersOr Akiva, Israel
HQ citystring
Or Akiva
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, branded prescription drugs, over-the-counter medications, biologics manufacturing, oligonucleotide therapeutics
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
No data
Revenue model3 records
1Branded Rx Products
TypeOne Time License
Description

Sale of innovative branded prescription pharmaceutical drugs across therapeutic areas

dexcel.com
2OTC Products
TypeOne Time License
Description

Sale of over-the-counter pharmaceuticals including national brands and private-label products

dexcel.com
3Generic Drugs
TypeOne Time License
Description

Sale of generic pharmaceutical products including established, niche, and first-to-market drugs in various dosage forms

dexcel.com
Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Branded Rx
Description

Innovative drugs across therapeutic areas

dexcel.com
+2 more records
Core offering1 text field

Dexcel Pharma develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (national brands and private-label over-the-counter pharmaceuticals), and Generics (established, niche, and first-to-market generic drugs in various dosage forms). The company operates R&D and manufacturing capabilities across small molecules, biologics, oligonucleotides, and genetic medicine, and commercializes products globally through its own affiliates, distributors, and partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Dexcel Pharma offers a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (over-the-counter national brands and private-label pharmaceuticals), and Generics (broad portfolio of established, niche, and first-to-market generic drugs in various dosage forms). The company is involved in development, manufacturing, and commercialization of these products globally.

Product and service1 record
1Branded Rx
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-headquartered generics and specialty manufacturer with broad US and European presence. Comparable diversified portfolio with strong generics focus.

TypeDirect peer
Description

Privately held Canadian pharma focused on generics, biosimilars, and innovative medicines. Comparable private ownership structure and generics-heavy portfolio.

TypeDirect peer
Description

Israeli-headquartered global pharma with a broad generics, specialty, and OTC portfolio. Most direct geographic and portfolio comparable to Dexcel, though significantly larger in scale.

4Sandoz (Novartis)
TypeDirect peer
Description

Global generics and biosimilars manufacturer spun out of Novartis. Closely comparable business model to Dexcel's generics and specialty segments with broader geographic reach.

TypeDirect peer
Description

Global pharma formed via Mylan-Upjohn merger, focused on generics, branded, and biosimilars. Comparable diversified product mix and global commercial footprint.

TypeDirect peer
Description

Consumer-focused pharma emphasizing OTC and store-brand generics. Highly comparable to Dexcel's OTC and private-label franchise and similar in size/scale.

TypeDirect peer
Description

MENA-headquartered pharma with branded, generic, and injectable businesses across the US, Europe, and MENA. Comparable mid-sized international footprint and product mix.

TypeDirect peer
Description

India-based global pharma with generics, APIs, and branded formulations across regulated and emerging markets. Comparable generic-plus-branded portfolio with international affiliates.

TypeDirect peer
Description

India-based pharma with generics, specialty, and biosimilars across US, Europe, and emerging markets. Similar diversified business model and therapeutic breadth.

10Endo International
TypeDirect peer
Description

Specialty and generics pharma with focus on sterile injectables and established brands. Comparable mid-sized diversified pharma operating model in US and select international markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dexcel Pharma

Pharmaceuticalsdexcelpharma.com

Dexcel Pharma is a privately held Israeli pharmaceutical company that develops, manufactures, and commercializes branded prescription drugs, generic medicines, and OTC products across multiple dosage forms. It serves healthcare providers, pharmacies, distributors, and consumers through subsidiaries in the US, Israel, UK, Germany, and Austria.

What Dexcel Pharma does

Dexcel Pharma is a privately owned pharmaceutical company headquartered in Or Akiva, Israel, with 1,001–5,000 employees. It develops, manufactures, and commercializes a diversified portfolio of branded prescription drugs, over-the-counter products (including national brands and private-label lines), and generic medicines—including established, niche, and first-to-market generics in various dosage forms. The company states R&D capabilities across multiple drug modalities: small molecules, biologics, oligonucleotides, and genetic medicine.

Dexcel commercializes its products globally through wholly-owned regional subsidiaries in five key markets—the United States (Dexcel USA), Israel (Dexcel Israel), the United Kingdom (Dexcel UK), Germany (Dexcel Germany), and Austria (Dexcel Austria)—supplemented by a network of third-party distributors and partners for broader geographic reach. Its customer base spans three primary segments: healthcare providers (physicians, hospitals, healthcare systems) for branded Rx, retail pharmacies and pharmaceutical distributors for OTC and generics, and end consumers purchasing OTC products through retail channels.

The revenue model is product-sale driven across all three product categories, with pricing not publicly disclosed. The company describes itself as investing in R&D and commercialization of novel drugs and technologies, and operates as an independent private entity with no disclosed parent company, institutional investors, M&A history, management roster, or financial metrics in the available source material.

Dexcel Pharma firmographics

Firmographics
Name
Dexcel Pharma
Legal name
Dexcel Pharma
Website
https://dexcelpharma.com
Company type
Private
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Dexcel Pharma is a privately held Israeli pharmaceutical company that develops, manufactures, and commercializes branded prescription drugs, generic medicines, and OTC products across multiple dosage forms. It serves healthcare providers, pharmacies, distributors, and consumers through subsidiaries in the US, Israel, UK, Germany, and Austria.
Ownership category
akta.pro rank

Dexcel Pharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Branded prescription drugs
  • Over-the-counter medications
  • Biologics manufacturing
  • Oligonucleotide therapeutics

Where Dexcel Pharma is headquartered

Location

Headquarters

HQ city
Or Akiva
HQ country
Israel
HQ region
Middle East

Offices5 records

Markets served

Dexcel Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Branded Rx Products: Sale of innovative branded prescription pharmaceutical drugs across therapeutic areas
  2. OTC Products: Sale of over-the-counter pharmaceuticals including national brands and private-label products
  3. Generic Drugs: Sale of generic pharmaceutical products including established, niche, and first-to-market drugs in various dosage forms

Distribution channels3 records

Dexcel Pharma product offering

Product offering

Core offering

Dexcel Pharma develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (national brands and private-label over-the-counter pharmaceuticals), and Generics (established, niche, and first-to-market generic drugs in various dosage forms). The company operates R&D and manufacturing capabilities across small molecules, biologics, oligonucleotides, and genetic medicine, and commercializes products globally through its own affiliates, distributors, and partners.

Product overview

Dexcel Pharma offers a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (over-the-counter national brands and private-label pharmaceuticals), and Generics (broad portfolio of established, niche, and first-to-market generic drugs in various dosage forms). The company is involved in development, manufacturing, and commercialization of these products globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Branded Rx: Innovative drugs across therapeutic areas
  • OTC
  • Generics

Products and services

  • Branded Rx

Companies that use Dexcel Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Dexcel Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Dexcel Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Dexcel Pharma competitors and assessment

Company assessment

Direct peers

  • Aurobindo Pharma: India-headquartered generics and specialty manufacturer with broad US and European presence. Comparable diversified portfolio with strong generics focus.
  • Apotex: Privately held Canadian pharma focused on generics, biosimilars, and innovative medicines. Comparable private ownership structure and generics-heavy portfolio.
  • Teva Pharmaceutical Industries: Israeli-headquartered global pharma with a broad generics, specialty, and OTC portfolio. Most direct geographic and portfolio comparable to Dexcel, though significantly larger in scale.
  • Sandoz (Novartis): Global generics and biosimilars manufacturer spun out of Novartis. Closely comparable business model to Dexcel's generics and specialty segments with broader geographic reach.
  • Viatris: Global pharma formed via Mylan-Upjohn merger, focused on generics, branded, and biosimilars. Comparable diversified product mix and global commercial footprint.
  • Perrigo Company: Consumer-focused pharma emphasizing OTC and store-brand generics. Highly comparable to Dexcel's OTC and private-label franchise and similar in size/scale.
  • Hikma Pharmaceuticals: MENA-headquartered pharma with branded, generic, and injectable businesses across the US, Europe, and MENA. Comparable mid-sized international footprint and product mix.
  • Dr. Reddy's Laboratories: India-based global pharma with generics, APIs, and branded formulations across regulated and emerging markets. Comparable generic-plus-branded portfolio with international affiliates.
  • Lupin Pharmaceuticals: India-based pharma with generics, specialty, and biosimilars across US, Europe, and emerging markets. Similar diversified business model and therapeutic breadth.
  • Endo International: Specialty and generics pharma with focus on sterile injectables and established brands. Comparable mid-sized diversified pharma operating model in US and select international markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Dexcel Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dexcel Pharma leadership team

Management profile

Number of profiles

Dexcel Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Dexcel Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dexcel Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexcel Pharma

What does Dexcel Pharma do?

Dexcel Pharma develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (national brands and private-label over-the-counter pharmaceuticals), and Generics (established, niche, and first-to-market generic drugs in various dosage forms). The company operates R&D and manufacturing capabilities across small molecules, biologics, oligonucleotides, and genetic medicine, and commercializes products globally through its own affiliates, distributors, and partners.

Is Dexcel Pharma a public or private company?

Dexcel Pharma is a private company. It is classified as unknown and is currently operating.

When was Dexcel Pharma founded?

Dexcel Pharma was founded in -1. It employs 1,001 to 5,000 people.

Where is Dexcel Pharma based?

Dexcel Pharma is headquartered in Or Akiva, Israel, in the Middle East region.

How does Dexcel Pharma make money?

Three revenue lines are on record. Branded Rx Products are the primary driver. The others are OTC Products and generic Drugs.

Who are Dexcel Pharma's main competitors?

Direct peers on record are Aurobindo Pharma, Apotex, Teva Pharmaceutical Industries, Sandoz (Novartis), Viatris, Perrigo Company, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Lupin Pharmaceuticals and Endo International.

Does Dexcel Pharma have an API?

No public API is recorded for Dexcel Pharma.

What industry is Dexcel Pharma in?

Dexcel Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales